Overview Phase II CT-2103/Carboplatin in Ovarian Cancer Status: Completed Trial end date: 2006-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer. Phase: Phase 2 Details Lead Sponsor: CTI BioPharmaTreatments: Albumin-Bound PaclitaxelCarboplatinPaclitaxelPaclitaxel poliglumex